Market Overview

FBR Raises Novavax Price Target From $2.25 To $10 As FDA's Informational Analysis Result Increases Firm's Confidence In A Successful Outcome Of The Prepare Trial


This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for NVAX

Mar 2018Seaport GlobalUpgradesNeutralBuy
Mar 2018JP MorganDowngradesNeutralUnderweight
Feb 2018CitigroupMaintainsNeutralNeutral

View More Analyst Ratings for NVAX
View the Latest Analyst Ratings

Posted-In: Analyst Color Price Target Analyst Ratings Trading Ideas


Related Articles (NVAX)

3 Reasons Why Big Lots Is Off Oppenheimer's Shopping List

Morgan Stanley: Epizyme Has 'Blockbuster' Cancer Drug In The Making